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Abstract 
Current pharmacotherapies for smoking have only modest efficacy with failure rates of up to 
90%. One potential target for new pharmacotherapies is the orexin/hypocretin system, a 
hypothalamic neuropeptide system involved in arousal, appetite and reward. The orexin 
system has been suggested as a potential therapeutic target for nicotine addiction because 
there are orexin/nicotine interactions following both acute and chronic nicotine 
administration, preclinical findings in animal models of nicotine addiction and some 
correlational studies in humans. Acute orexin administration activates cholinergic neurons 
and acute nicotine administration activates orexin neurons, while chronic nicotine causes an 
upregulation in orexin peptides and receptors while decreasing the availability of orexin 
binding sites. A small number of preclinical studies in animal models of nicotine addiction 
have found effects of orexin antagonists in reducing nicotine self-administration and/or 
reinstatement behavior, but results are not always entirely consistent between studies. A few 
human studies have found negative correlations between orexin levels and measures of 
nicotine craving in humans, or genetic associations between hypocretin receptor 
polymorphism and nicotine dependence. However, further research is required to reconcile 
discrepancies in the preclinical literature and to understand the role of the orexin system in 
nicotine dependence before clinical trials can be proposed.  
Definitions 
 
Almorexant. A dual orexin receptor antagonist that progressed to clinical trials. 
 
Dual orexin receptor antagonist. A compound that has antagonist effects at both orexin 
receptors. 
 
Fixed-ratio self-administration. Operant reinforcement schedule used in preclinical animal 
models where a reward is earned for a fixed number of operant responses. 
 
Hypocretin. The orexin/hypocretin system named based on its hypothalamic distribution and 
similarity to the incretin family of hormones. Refers to the genes HCRT/Hcrt, which encodes 
for the two peptides, HCRTR1/Hcrtr1 and HCRTR2/Hcrtr2 which encode for the two 
receptors respectively. 
 
Orexin. The orexin/hypocretin system named based on its role in appetitive behaviour. Refers 
to the two peptides, orexin-A and orexin-B, which bind to the OX1 and OX2 receptors. 
 
Progressive ratio. Operant reinforcement schedule used in preclinical animal models where 
the number of responses required to earn each subsequent reward increases. 
 
Reinstatement. A model of relapse-like behaviour which involves the return of a previously 
extinguished behaviour. May be precipitated by drug-priming, reward-associated cues, 
contexts or stress. 
 
SB-334867. A selective OX1 receptor antagonist. 
 
SORA-18.  A selective OX2 receptor antagonist. 
 
TCS-OX2-29. A selective OX2 receptor antagonist. 
 
TCS 1102.  A dual orexin receptor antagonist. 
  
Key Facts of the Orexin System 
 
• Discovered simultaneously by two groups in 1998. 
• Two peptides encoded by the hypocretin gene, orexin-A and orexin-B, bind to 
excitatory G-protein coupled receptors, OX1 and OX2. 
• Loss of orexin neurons involved in human narcolepsy. 
• Stimulation of orexin system promotes appetitive behaviour. 
• Animal studies have demonstrated roles for the orexin in multiple drugs of abuse. 
• Suvorexant (Belsomra®) was the first orexin-based pharmacotherapy and was 




• This chapter focuses on the orexin system, a neuropeptide system involved in arousal, 
appetite and reward, and its potential as a therapeutic target for nicotine addiction. 
• The orexin system activates cholinergic neurons and is activated by nicotine 
administration, with chronic nicotine causing altered expression of the hypocretin 
genes and orexin peptides. 
• A small number of preclinical animal studies have shown effects of various orexin 
receptor antagonists in self-administration or reinstatement paradigms. 
• However, there are substantial differences in methodologies between studies and 
some studies have not found effects of orexin antagonism. 
• The limited number of studies in animals and humans suggests that there may be 
some promise in targeting the orexin system, but more research is required to 
understand its role in nicotine seeking before clinical trials can be proposed. 
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List of abbreviations 
 
Acb. Nucleus accumbens 
 
DMH. Dorsomedial hypothalamus 
 
FRn. Fixed ratio of n responses 
 
GPCR. G-protein coupled receptor 
 
LH. Lateral hypothalamus 
 






PeF. Perifornical hypothalamus 
 
PFC. Prefrontal cortex 
 
PR. Progressive ratio 
 
VTA. Ventral tegmental area  
Current pharmacological therapies for smoking have only modest efficacy with failure 
rates of up to 90% (Cahill, Lindson-Hawley, Thomas, Fanshawe, & Lancaster, 2016). The 
orexin/hypocretin system has been suggested as a potential therapeutic target and is in clinical 
trials for cocaine (The University of Texas Health Science Center, 2016). Here we review the 
orexins as a potential therapeutic target for nicotine because there is evidence for both acute 
and chronic nicotine/orexin interactions and some preliminary evidence that orexin-based 
medications may be effective in reducing smoking. However, while there is promise there are 
some conflicting preclinical results and only correlational results in human studies are 
available. 
The orexin/hypocretin system is a neuropeptide system involved in arousal, appetite, 
and reward. Orexin neurons originate exclusively from the lateral hypothalamus (LH), 
perifornical hypothalamus (PeF) and dorsomedial hypothalamus (DMH; Baldo, Daniel, 
Berridge, & Kelley, 2003; Elias et al., 1998; Peyron et al., 1998). Orexin fibres project to key 
mesocorticolimbic reward regions (Figure 1), such as the ventral tegmental area (VTA), 
nucleus accumbens (Acb) and prefrontal cortex (PFC; Baldo et al., 2003; Peyron et al., 1998) 
where there are abundant nicotinic acetylcholine receptors (nAChRs; Lerman et al., 2007).  
The orexin system is composed of two peptides, orexin-A and orexin-B (OX-A and 
OX-B respectively), and two GPCRs, OX1 and OX2 (Figure 2; Sakurai et al., 1998). Hypocretin 
(Human: HCRT, Rat/Mouse: Hcrt) mRNA encodes for the prepro-orexin precursor peptide 
which is cleaved to form the OX-A and OX-B peptides (Sakurai et al., 1999). OX-A binds non-
selectively to both receptors while OX-B shows some selectivity for the OX2 receptor. Both 
OX1 and OX2 are excitatory and produce elevated Ca2+ suggesting Gαq-mediated signaling (de 
Lecea et al., 1998; Sakurai et al., 1998) but they can also interact with multiple second 
messenger pathways (Kukkonen & Leonard, 2014). Orexin receptors also form complexes, 
which may be homodimers (Xu, Ward, Pediani, & Milligan, 2011), OX1 and OX2 heteromers, 
Figure 1: Anatomic overlap between the orexin system and nicotinic acetylcholine 
receptors.   
Legend to Figure 1: Orexin receptors are present in varying densities in key brain regions 
involved in reward. Nicotinic acetylcholine receptors (nAChRs) are present in all of these 












Figure 2: Schematic overview of orexin signalling molecules. 
 
Legend to Figure 2: The two orexin peptides are cleaved from a single precursor and bind to 
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CB1 or CRF receptor complexes (Ellis, Pediani, Canals, Milasta, & Milligan, 2006; Jäntti, 
Mandrika, & Kukkonen, 2014; Navarro et al., 2015). Thus, orexin signaling is thought to be 
excitatory with a Gαq-mediated signaling cascade, but with the potential for interactions with 
co-transmitters and heteromeric receptor complexes. 
Neuroanatomical and Molecular Interactions 
Acute Nicotine and Orexin 
The orexin system has been suggested as a potential therapeutic target because of the 
neuroanatomical and molecular interactions between the cholinergic and orexinsystems. 
Interactions occur following both acute and chronic nicotine administration. Cholinergic 
neurons are activated by OX-A application (Fadel, Pasumarthi, & Reznikov, 2005) and orexin 
neurons are activated by acute systemic nicotine administration (Figure 3; Pasumarthi, 
Reznikov, & Fadel, 2006). Importantly, this activation, as measured by c-Fos 
immunohistochemistry, appears to be specific in the hypothalamus for orexin neurons, 
suggesting that the orexins play a key role in nicotine-mediated effects. While this effect is 
blocked by both the non-selective nAChR antagonist mecamylamine and the α4β2 nAChR 
antagonist DHβE, DHβE alone increased medial hypothalamic orexin neuron activation, but 
blocked nicotine-induced activation (Pasumarthi et al., 2006), suggesting that there is 
endogenous cholinergic regulation of the orexin system. Nicotine-induced activation of orexin 
neurons appears to be specific to hypothalamic projections to the basal forebrain and 
paraventricular thalamus (Pasumarthi & Fadel, 2008). In addition to systemic nicotine 
administration, orexin neurons can also be activated by local nicotine application to the 
hypothalamus which produces increased ACh and glutamate efflux in the hypothalamus 
(Pasumarthi & Fadel, 2010). These results demonstrate interactions between orexin, which 
Figure 3: Acute orexin/nicotine interactions. 
 
Legend to Figure 3: (A) Acute orexin can activate cholinergic neurons and (B) acute 

















activates cholinergic neurons, and acute nicotine administered systemically or directly to the 
hypothalamus that activates orexin neurons. 
Chronic Nicotine and Orexin 
Studies of chronic nicotine administration have shown alterations in regulation of 
hypocretin gene expression and orexin peptides (Figure 4). Chronic nicotine administration (14 
days) increases levels of mRNA encoding the prepro-orexin peptide and orexin receptors (Kane 
et al., 2000). Blockade of nAChRs in nicotine-exposed rats decreases orexin neuron activation 
(Simmons et al., 2016). Measurements of protein show that in the DMH, chronic nicotine 
increase both OX-A and OX-B, while OX-B is elevated in the paraventricular nucleus (Kane 
et al., 2000). However, chronic nicotine also decreases hypothalamic bindings sites available 
for OX-A (Kane, Parker, & Li, 2001). This desensitization appears to occur by obscuring 
binding sites but without internalization because OX-A continued to bind, but with lower 
affinity (Kane et al., 2001). Although a more direct demonstration of the exact mechanism of 
nicotine-induced decrease in binding sites has never been reported in the literature, these results 
demonstrate that chronic nicotine administration has regulatory effects on both hypocretin gene 
expression and levels of orexin peptide. 
Orexin as a Therapeutic Target for Nicotine Dependence 
Nicotine Self-Administration 
Preclinical studies of orexin as a potential therapeutic target for nicotine addiction have 
found effects of both selective and non-selective (dual) orexin receptor antagonists (Table 1). 
The first direct demonstration of a role for orexins in nicotine seeking behaviour involved 
administration of the OX1 receptor antagonist SB-334867 systemically and into the insular 
cortex (Hollander, Lu, Cameron, Kamenecka, & Kenny, 2008). OX1 receptor antagonism 
selectively suppressed the number of nicotine infusions earned on fixed-ratio-5 (FR5) and 
Figure 4: Effects of chronic nicotine on orexin regulation. 
 
Legend to Figure 4. Chronic nicotine upregulates expression of orexin peptides and 
receptors while but reduces the availability of binding sites for OX-A without receptor 
internalisation. 
  
Table 1: Comparison of behavioural studies examining nicotine self-administration and reinstatement. 
Animals Food Restriction Pretraining Training Measure Drug Outcome Reference 
Pair-housed 
male Wistars 






7 – 14 days 
FR5TO20  SB-334867 (i.p.) ↓ Hollander et 
al. (2008) 
    PR SB-334867 (i.p.) ↓  






18 g/day Food until 100 
pellets/1 h 
Lever, 
40 ± 4.5 days 

































Ad libitum None Daily nicotine 
prime, nosepoke, 
10 days 










25 g/day Food FR1 Lever, FR1 x 5 
days, FR2 x 2 
days, FR5 x 6 
days 
PR 2-SORA 18 (p.o.) No effect Uslaner et al. 
(2014) 
   Animals retrained 
FR5 x 3 days  
Cue reinstatement 
Nic reinstatement 
2-SORA 18 (p.o.) 







20 g/day None Nosepoke,  
10 days 
FR1TO24 TCS 1102 (i.c.v.) No effect Khoo et al. 
(2017) 
   Animals retrained 






TCS 1102 (i.c.v.) 
TCS 1102 (i.c.v.) 





Legend to Table 1:  Details of key parameters of preclinical studies and the direction of effect.
progressive ratio (PR) schedules, while leaving the number of food pellets earned unaffected. 
Similarly, intra-insular administration of SB-334867 reduced FR5 nicotine infusions but not 
the number of food pellets earned (Hollander et al., 2008). These results have been replicated 
using SB-334867 and the dual orexin receptor antagonist almorexant (LeSage, Perry, Kotz, 
Shelley, & Corrigall, 2010). The number of nicotine infusions earned was reduced on an FR5 
schedule by both the OX1 receptor antagonist SB-334867 and the dual orexin receptor 
antagonist almorexant. However, while SB-334867 in this study also left the number of food 
pellets earned unaffected, the highest dose of almorexant reduced pellets earned. LeSage et al. 
(2010) further extended the findings of Hollander et al. (2008) by examining Hcrtr1 and Hcrtr2 
gene expression and finding decreased Hcrtr1 in the rostral LH immediately after nicotine self-
administration but not 5 h after a self-administration session, while arcuate nucleus had 
increased Hcrtr1 mRNA 5 h but not immediately after self-administration. These consistent 
results from different groups provided strong indications that the orexins might be a potential 
target for the treatment of nicotine addiction. 
Reinstatement of Nicotine Seeking 
In addition to regulating self-administration of nicotine, it has also been shown that 
orexin signaling plays a role in the reinstatement of nicotine seeking but results have not been 
consistent. Intracerebroventricular administration of OX-A can reinstate extinguished nicotine 
seeking behaviour in mice, an effect that can be blocked by administration of the OX1 receptor 
antagonist SB-334867 (Plaza-Zabala, Martín-García, de Lecea, Maldonado, & Berrendero, 
2010). While OX1 receptor antagonism reduces anxiety-like behaviour in the elevated plus 
maze induced by acute injections of nicotine, suggesting that orexins are involved in the 
anxiogenic effects of acute nicotine OX1 receptor antagonism does not affect footshock-
induced reinstatement, indicating that these behaviours are mediated by separate processes 
(Plaza-Zabala et al., 2010). During cue-induced reinstatement of nicotine-seeking in mice, an 
increased percentage of orexin neurons in the PeF and LH show signs of activation as measured 
by c-Fos (Plaza-Zabala et al., 2013). Selective OX1 receptor antagonist using SB-334867 but 
not OX2 receptor antagonism using TCS-OX2-29 can attenuate this cue-induced reinstatement 
(Plaza-Zabala et al., 2013). However, it has been shown that a different selective OX2 receptor 
antagonist (SORA-18) was able to reduce cue-induced reinstatement in rats, but not nicotine-
primed reinstatement or PR self-administration (Uslaner et al., 2014). These studies suggest 
that the role of orexin signaling in reinstatement behaviours is inconsistent and may depend on 
the proximal cause of reinstatement or the behavioural model used. In both rats and mice, cue-
induced reinstatement has been reduced using orexin receptor antagonists, but it is unclear 
whether the OX2 receptor is involved. While these results are suggestive of a role for the 
orexins in cue-induced reinstatement for nicotine, the relatively small number of studies and 
the variance in training protocols (Table 1) makes it difficult to draw strong conclusions. 
Withdrawal and Motivation 
Preclinical studies have also demonstrated roles for orexin signaling in other nicotine-
related behaviours. In mice made dependent by 25 mg/kg/day nicotine administered for 14 days 
by osmotic minipump, mecamylamine-precipitated withdrawal was attenuated in Hcrt-/- mice 
or mice given the OX1 receptor antagonist SB-334867 (Plaza-Zabala, Flores, Maldonado, & 
Berrendero, 2012), suggesting that orexins mediate withdrawal symptoms. Orexin signaling in 
the paraventricular nucleus of the hypothalamus was particularly implicated because targeted 
microinjection of SB-334867 attenuated behavioural signs of nicotine-withdrawal. Although 
Plaza-Zabala et al. (2012) did not find effects of the OX2 receptor antagonist TCS-OX2-29, 
this may have been because they did not use a sufficiently high dose. Their doses of 5-10 mg/kg 
TCS-OX2-29 (Plaza-Zabala et al., 2012; Plaza-Zabala et al., 2013) were lower than the 10-30 
mg/kg doses used by Smith, See, and Aston-Jones (2009) although these also produced null 
results for cocaine. A previous study that reported positive effects at OX2 receptors used a 15 
mg/kg dose of SORA-18, which has greater potency than TCS-OX2-29 (Hirose et al., 2003; 
Uslaner et al., 2014). The dual orexin receptor antagonist, TCS 1102, also attenuated nicotine-
potentiated PR responding and nicotine-induced reinstatement for sucrose pellets (Winrow et 
al., 2010). These results also provide support for a potential use for orexin receptor antagonists 
in treating nicotine addiction because they might reduce symptoms of withdrawal or reduce 
other reward-related nicotine responses. 
Divergent Findings 
However, we recently reported that the dual orexin receptor antagonist TCS 1102 had 
no effect on nicotine self-administration, cue-induced reinstatement, nicotine-primed 
reinstatement and had at most a small transient effect on cue and prime-induced reinstatement 
only after chronic nicotine self-administration (Khoo, McNally, & Clemens, 2017). Although 
TCS 1102 has previously been shown to be effective in reducing behavioural responses to 
nicotine (Winrow et al., 2010) and we found that intracerebroventricular TCS 1102 could 
attenuate OX-A-induced increases in feeding behaviour, we found no evidence of any effect of 
dual orexin receptor antagonism that could have clinical relevance. We suspect that this 
discrepancy between our study and previous findings may be due to several differences in 
protocols. For example, our rats were trained on FR1, while previous studies have generally 
used FR5 schedules of reinforcement and food pre-training protocols (Hollander et al., 2008; 
LeSage et al., 2010; Uslaner et al., 2014). In our study, rats were trained to make nosepokes 
for nicotine for the entire duration of training with no period of operant responding for food 
(Khoo et al., 2017). This may have resulted in relatively lower levels of motivation in our 
animals. It has previously been argued that nicotine has relatively weak primary reinforcing 
properties but may act to enhance the motivational properties of other reinforcers and 
conditioned stimuli (Chaudhri et al., 2006). If this is the case, the food pre-training protocols 
used in previous demonstrations of orexinergic regulation of nicotine seeking or self-
administration may have potentiated the motivational properties of the conditioned reinforcers 
and responses that were ultimately paired with nicotine. It has previously been shown that food 
pre-training enhances acquisition (Bongiovanni & See, 2008; Clemens, Caillé, & Cador, 2010; 
Garcia, Lê, & Tyndale, 2014). For example, sucrose pre-training can facilitate later cue-
induced reinstatement of nicotine seeking for rats trained to make nosepokes (Clemens et al., 
2010), but food pre-training does not appear to affect later reinstatement tests in rats trained to 
press levers (Garcia et al., 2014). Differences in pre-training protocols could also explain why 
relatively few rats in our experiments would self-administer under an FR5 schedule of 
reinforcement (unpublished observations).  
These negative results urge caution in seeking to translate orexin antagonists to the 
clinic, but they do not necessarily exclude orexin-based therapies for nicotine. In humans, 
nicotine is often used in combination with other drugs (Cross, Lotfipour, & Leslie, 2017). For 
example, nicotine increases alcohol consumption in men (Acheson, Mahler, Chi, & de Wit, 
2006; Barrett, Tichauer, Leyton, & Pihl, 2006) and subjective feelings of drunkenness (Kouri, 
McCarthy, Faust, & Lukas, 2004), results which have been replicated in animal models 
(Kalejaiye, Bhatti, Taylor, & Tizabi, 2013; Lê, Funk, Lo, & Coen, 2014). Nicotine use is also 
associated with using or becoming dependent on cannabis (Taylor et al., 2017), cocaine 
(Budney, Higgins, Hughes, & Bickel, 1993; Gorelick, Simmons, Carriero, & Tashkin, 1997) 
and methamphetamine (Grant et al., 2007). Using multiple drugs might increase the 
motivational salience and render nicotine subject to orexinergic regulation. Other drugs of 
abuse also have stronger evidence for orexinergic regulation and there is currently a clinical 
trial for using the dual orexin receptor antagonist, suvorexant, in the treatment of cocaine 
dependence (The University of Texas Health Science Center, 2016). However, further 
preclinical studies in animal models of polydrug use are required to establish whether this is 
the case. 
Human Studies 
A few studies in humans have found associations between the orexin system and 
nicotine (Table 2). Human studies have reported a negative correlation between orexin plasma 
concentration and self-reported nicotine craving (von der Goltz et al., 2010), and reduced Hcrt 
mRNA expression in blood samples in smokers compared to non-smokers  (Rotter et al., 2012). 
Although these studies are consistent, they are limited by their peripheral measurement of 
orexin peptide or Hcrt mRNA. While the OX-A peptide can diffuse across the blood-brain 
barrier, OX-B has low lipophilicity and is rapidly metabolised (Kastin & Akerstrom, 1999). 
Genome-wide association studies have found that in Japanese samples, a single-nucleotide 
polymorphism in the HCRTR2 gene was associated with increased risk of smoking (Nishizawa 
et al., 2015). However, results from these studies should be interpreted with caution because it 
has been argued that genome-wide association studies produce little useful data when 
examining complex traits (Boyle, Li, & Pritchard, 2017), although previous studies have 
yielded associations between targets that are biologically relevant or already targets for current 
therapeutics (Visscher, Brown, McCarthy, & Yang, 2012). While Nishizawa et al. (2015) found 
associations between HCRTR2 polymorphism and smoking, methamphetamine and 
schizotypal trait scores, but they also found associations with goiter, aortic aneurysm and 
myeloma. The current small array of human studies of the orexin system and nicotine suggest 
that there may be some linkage, but this is correlational and further studies in animals and 
humans are required to better establish whether the orexin system really is involved in nicotine 
seeking. 
Implications for Treatments 
There is currently insufficient evidence to recommend orexin-based treatments for 
smoking. Although there are some promising preclinical results and correlational evidence has 
  
Table 2: Human correlational studies. 
Participants Measurements Findings Reference 














with plasma OX 
(von der Goltz et al., 
2010) 
36 cannabis dependent, 20 
smoking, 21 non-smoking 
student-acquaintances 
Whole blood: 
HCRT and OX-A 
in peripheral blood 
lymphocytes 
 
Lower OX-A in 
smokers 
 
No effect on HCRT 
promoter methylation 
(Rotter et al., 2012) 
Initial GWAS: 148 
patients 
 
Followup: 112 abdominal 
surgery patients, 203 
methamphetamine 
dependent patients, 311 
healthy volunteers 
 
2305 autopsy cases 














(Nishizawa et al., 
2015) 
Legend to Table 2: Summary of key findings from human studies to date. GWAS, genome-
wide association study.  
been found in humans, there are also some inconsistent findings in the preclinical literature that 
should be addressed. Further studies are required to examine the relationship between an 
animal’s training history and orexinergic regulation of nicotine seeking. 
Conclusion 
The orexin system has generated much excitement and interest for its therapeutic 
potential for a variety of disorders. This potential has recently been realised with the approval 
of suvorexant for insomnia (Coleman, Gotter, Herring, Winrow, & Renger, 2017) and may be 
realised for cocaine addiction (The University of Texas Health Science Center, 2016). Animal 
studies show that acute nicotine stimulates orexin neurons and chronic nicotine can have affect 
the regulation of the orexin system. Preclinical animal models of drug self-administration and 
seeking have tested orexin antagonists against nicotine less frequently than against other drugs 
of abuse, but from a relatively small pool of studies there is a mix of both positive and negative 
findings regarding the efficacy of orexin antagonists on nicotine self-administration and 
reinstatement. Research with human participants has found some consistent associations 
between orexin downregulation and nicotine use, as well as genetic associations between a 
single-nucleotide HCRTR2 polymorphism and smoking, but these results are correlational. For 
nicotine and orexin, there is currently insufficient evidence that it would be a useful therapeutic 
target for nicotine addiction but further studies are required to examine the reasons behind 
differential outcomes in preclinical research and to follow up on the associations that have been 
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